- Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.
Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.
The Pediatric infectious disease journal (2007-12-29)
Todd Hatchette, Graham A Tipples, Geoff Peters, Ahmed Alsuwaidi, Jianwei Zhou, Timothy Lloyd Mailman
PMID18162946
ABSTRACT
The authors describe an acyclovir-resistant varicella zoster virus infection in a pediatric patient after hematopoietic stem cell transplant, the use of foscarnet as salvage therapy, and review the literature to clarify the pediatric experience with foscarnet in this setting. A novel thymidine kinase mutation is described, along with a new phenotypic assay for characterizing acyclovir resistance in varicella zoster virus.
MATERIALS
Product Number
Brand
Product Description
Aciclovir, European Pharmacopoeia (EP) Reference Standard
Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard
Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard